Defining and searching pharmacogenetics and pharmacogenomics to identify its core research journals

Science and Technology Libraries

Volumn 26, Issue 1, 2005, Pages 69-88

  Lascar, Claudia ^a   Barnett, Philip ^a  

^a CITY COLLEGE OF NEW YORK   (United States)

Author keywords

Bibliographic databases; Collection development; Pharmacogenetics; Pharmacogenomics

Indexed keywords

BIBLIOGRAPHIC RETRIEVAL SYSTEMS; BIOTECHNOLOGY; DATABASE SYSTEMS; DIGITAL LIBRARIES; DRUG PRODUCTS; MEDICINE; MOLECULAR BIOLOGY; ONLINE SYSTEMS;

BIBLIOGRAPHIC DATABASES; COLLECTION DEVELOPMENT; PHARMACOGENETICS; PHARMACOGENOMICS;

ONLINE SEARCHING;

EID: 30644459358     PISSN: 0194262X     EISSN: 15411109     Source Type: Journal    
DOI: 10.1300/J122v26n01_05     Document Type: Article

References (27)

1. Barillot, Marine J., Bernard Sarrut, and Christian G. Doreau. (1990). "Evaluation of Drug Interaction Document Citation in Nine On-Line Bibliographic Databases." Annals of Pharmacotherapy, 31 (1): 45-9.
2. Barnett, Philip. (1993). "Defining, Collecting and Searching the Neurochemistry Literature." Science & Technology Libraries, 13(3/4): 39-56.
3. Barnett, Philip. (2002). "Combinatorial Chemistry: A Guide for Librarians." Issues in Science & Technology Librarianship, 33 (Winter 2002) http://www.istl.org/02-winter/refereed.html.
4. Biarez, Odile, Bernard Sarrut, Christian G. Doreau, and Jean Etienne. (1991). "Comparison and Evaluation of Nine Bibliographic Databases Concerning Adverse Drug Reactions." DICP: The Annals of Pharmacotherapy, 25(10): 1062-5.
5. Buchanan, Allen E., Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John Robertson, and Baruch Brody. (2002). "Pharmacogenetics: Ethical Issues and Policy Options." Kennedy Institute of Ethics Journal, 12(1): 1-15.
6. Burchell, Brian. (2003). "Genetic Variation of Human UDP-glucuronosyltransferase: Implications in Disease and Drug Glucuronidation." American Journal of Pharmacogenomics, 3(1): 37-52.
7. Desta, Zeruesenay, Xiaojiong Zhao, Jae-Gook Shin, and David A. Flockhart. (2002). "Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism." Clinical Pharmacokinetics, 41 (12): 913-58.
8. DeVane, Lindsay C., and Charles B. Nemeroff. (2002). "Clinical Focus: 2002 Guide to Psychotropic Drug Interactions." Primary Psychiatry, 9(3): 28-57.
9. Ensom, Mary H.H., Thomas K.H. Chang, and Payal Patel (2001). "Pharmacogenetics: The Therapeutic Drug Monitoring of the Future?" Clinical Pharmacokinetics, 40(11): 783-802.
10. Evans, William E., and Howard L. McLeod. (2003). "Pharmacogenomics-Drug Disposition, Drug Targets, and Side Effects." New England Journal of Medicine, 348(6): 538-549.
11. Evans, William E., Howard L. McLeod. and Mary V. Relling. (2004). "Moving Towards Individualized Medicine with Pharmacogenomics." Nature 429(6990): 464-468.
12. Ingelman-Sundberg, Magnus. (2005). "Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity." Pharmacogenomics Journal, 5(1): 6-13.
13. Kaiow, Werner. (1990). "The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture: Pharmacogenetics: Past and Future." Life Sciences, 47(16): 1385-1397.
14. Lazarou, Jason, Bruce H. Pomeranz, and Paul N. Corey. (1998). "Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies." JAMA, 279(15): 1200-1205.
15. Lesko Lawrence J., Ronald A. Salerno, Brian B. Spear et al. (2003). "Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop." Journal of Clinical Pharmacology, 43(4): 342-358.
16. Omura, Tsuneo. (1999). "Forty Years of Cytocrome P450." Biochemical and Biophysical Research Communications, 266(3): 690-698.
17. Morris, Theodore A. and Katherine W. McCain. (1998). "The Structure of Medical Informatics Literature." Journal of the American Medical Informatics Association, 5(5): 448-466.
18. Sayers, Mary, John Joice, and David Bawden. (1990). "Retrieval of Biomedical Reviews: A Comparative Evaluation of Online Databases for Reviews of Drug Therapy." Journal of Information Science, 16(5): 321-325.
19. Schwatz U.I. (2003). "Clinical Relevance of Genetic Polymorphisms in the Human CYP2C9 Gene." European Journal of Clinical Investigation, 33(Suppl 2): 23-30.
20. Shi, Michael M., Michael R. Bleavins, and Felix A. De La Inglesia. (2001). "Pharmacogenetic Application in Drug Development and Clinical Trials." Drug Metabolism and Disposition, 29(4 Pt 2): 591-595.
21. Shrode, Flora G. (1997). "Science and Patent Sessions at Online World, Sept. 16, 1997 Washington, D.C." Issues in Science and Technology Librarianship, 16 (Fall 1997). http://www.istl.org/97-fall/ conference1.html.
22. Simmons, Edlyn, S. and Stuart M. Kaback. (1996). "Patents, Literature." In Encyclopedia of Chemical Technology, Fourth Edition, Volume 18, edited by Jacqueline I. Kroschwitz and Mary Howe-Grant, pp. 102-156. New York: John Wiley & Sons.
23. Spear, Brian B., Margo Heath-Chiozzi and Jeffrey Huff. (2001). "Clinical Applications of Pharmacogenetics." Trends in Molecular Medicine, 7(5): 201-204.
24. United States Food and Drug Administration, Department of Health and Human Services. (1997). "Guidance for Industry Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro." Rockville, MD: The Drug Information Branch (HFD-210), April 1997. http://www.fda.gov/cder/guidance/clin3.pdf.
25. United States Food and Drug Administration, Department of Health and Human Services. (2003). "Guidance for Industry: Pharmacogenomic Data Submissions." Rockville, MD: The Drug Information Branch (HFD-210), November 2003. http://www.fda.gov/cder/guidance/5900dft.pdf.
26. Vogel, Friederich. (1959). "Moderne probleme der humangenetik." Ergebisse Inneren Medizin und Kinderheilkdunde, 12: 52-125.
27. Weinshilboum, Richard. (2003). "Inheritance and Drug Response." New England Journal of Medicine, 348(6): 529-537.